Attapon Cheepsattayakorn1,2*, Ruangrong Cheepsattayakorn3 and Prajak Boonjitpimol1
1Faculty of Medicine, Western University, Pathumtani Province, Thailand
210th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand
3Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
*Corresponding Author: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.
Received: June 28, 2021 ; Published: July 09, 2021
Endocrinological sequelae in post-acute-COVID-19 phase may be caused by iatrogenic complications, immunological and inflammatory damage, and direct SARS-CoV-2 (COVID-19) invasion, including apparently pre-existing diabetes mellitus during acute COVID-19 phase and can be long-term treated with antidiabetic agents other than insulin, although initially related to diabetic ketoacidosis (DKA) [1]. Primary deficit in insulin production may be mediated by several factors, such as infection stress response accompanying peripheral insulin resistance or inflammation [1]. Thus, reversion of COVID-19-related diabetes, nor that its outcomes difference in COVID-19 long haulers is not confirmed [2]. Lasting damage of the pancreatic β cells is still not confirmed although demonstrated ACE 2 and TMPRSS2, involving in SARS-CoV-2 (COVID-19)-cell-entry expression in pancreatic β cells [3]. Interruption of anabolic or antiresorptive agents, vitamin D insufficiency, exposure to corticosteroids, immobilization, and bone demineralization associated with systemic inflammation are also the COVID-19 risk factors [2]. Patients with newly diagnosed diabetes mellitus in the absence of traditional risk factors for type 2 diabetes should be performed serologic testing for type 1 diabetes-related autoantibodies repeated post-prandial C-peptide measurements at the follow-up, while patients with such risk factors can be similarly treatable to ketosis-prone type 2 diabetes [4]. New-onset Graves’ disease should be excluded before treating post-acute-COVID-19-illness patients with incident hyperthyroidism with corticosteroids due to SARS-CoV-2 (COVID-19)-associated destructive thyroiditis [5].
Citation: Attapon Cheepsattayakorn., et al. “Endocrinological Sequelae-Associated Post-Acute-Covid-19-Illness ”. Acta Scientific Microbiology 4.8 (2021): 17-18.
Copyright: © 2021 Attapon Cheepsattayakorn., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.